Abstract: Purpose/Background: Clozapine is associated with hematological abnormalities, with neutropenia and agranulocytosis of most concern. Granulocyte colony-stimulating factor (G-CSF) has been used to support clozapine rechallenge after neutropenia with the aim of maintaining the neutrophil count. This study aims to explore the practice, use, safety, and efficacy of G-CSF in this context.
C lozapine remains the criterion standard treatment of treatmentresistant schizophrenia 1 and is associated with clinical response in 50% to 60% of patients with treatment-resistant schizophrenia. 2, 3 However, its use is restricted because of the risk of potentially life-threatening adverse events. 4 In particular, clozapine use has a risk of agranulocytosis, and in many countries, the emergence of neutropenia, which can presage agranulocytosis, means that clozapine must be discontinued. 5 Rechallenge after clozapine-associated neutropenia carries significant risk, especially after an episode of clozapine-associated agranulocytosis where recurrence of neutropenia on rechallenge occurs in 80% of patients in contrast to 30% after a neutropeniarelated discontinuation. 6 In an earlier retrospective case review, 38% of cases overall developed a neutropenia on clozapine rechallenge, and for 85% of these, the neutropenia occurred more quickly and was more severe than that during the first clozapine trial. Furthermore, for 65% of the patients who developed a further neutropenia on rechallenge, the neutropenia was longer in duration than the original episode. 7 More recently, granulocyte colony-stimulating factors (GCSFs) and granulocyte-macrophage colony-stimulating factors (GM-CSFs) have been used in specialist centers with the aim of preventing the recurrence of neutropenia on clozapine rechallenge. However, this practice has not been systematically reviewed.
Therefore, in this study, we aimed to synthesize the published data to review the efficacy of G-CSF during clozapine rechallenge for the prevention of recurrence of clozapine-associated neutropenia or agranulocytosis, to describe the dose and frequency of G-CSF used, and to review adverse incidents.
METHODS
We performed a systematic literature search to identify all published interventional and observational studies, case series, and case reports, up until September 2016, investigating or describing G-CSF use as either a regular or an as-required administration, to support resumption and maintenance of clozapine treatment. We defined as-required administrations as those cases in which there was an a priori plan to administer G-CSF in single or consecutive G-CSF doses in the event of a neutropenic episode (as defined by the individual case reports) and where G-CSF was discontinued upon neutrophil recovery. Regular administration was defined as regular use of prophylactic G-CSF, even where the neutrophil count was normal or high. This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses standard. 8 
Inclusion Criteria
Studies were included in this systematic review if they (1) included participants (no age restriction) who had a clozapine rechallenge after an episode of clozapine-associated neutropenia, (2) included participants who were treated prophylactically with regular G-CSF or with as-required administrations of G-CSF to enable continued clozapine use during rechallenge; and (3) were published in a peer-reviewed journal.
Exclusion Criteria
Studies were excluded if (1) G-CSF was used to support the maintenance of clozapine treatment during chemotherapy, (2) there were insufficient laboratory data to permit inclusion of the report, and (3) G-CSF was not used to support continued clozapine use during a rechallenge.
Information Sources and Searches
Two independent reviewers (J.L. and S.M.) performed a search using Medline, EMBASE, Scopus, and Google Scholar from inception to September 2016. The following search terms were used, both alone and in combinations: granulocyte colony-stimulating factor OR granulocyte-macrophage colony-stimulating OR GCSF OR G-CSF OR GMCSF OR GM-CSFAND clozapine OR clozaril OR denzapine OR zaponex OR leponex.
In addition, the reference lists of the retrieved articles and relevant review articles were examined for cross-references.
Study Selection and Exclusion
All abstracts meeting the criteria were obtained and independently examined by the authors (J.L. and S.M.). The 2 appraisers applied the eligibility criteria to produce a list of full-text articles. There was no search for unpublished works, although authors were contacted for clarification where necessary. Reference lists were searched for additional studies.
Primary Outcome
The primary outcome was the continuation of clozapine with white cell and neutrophil count within the allowed ranges for continued clozapine prescription (ie, white cell count >3.0 Â 10 9 /L and absolute neutrophil count [ANC] >1.5 Â 10 9 /L) at the end of follow-up, which was designated a "successful outcome."
Secondary Outcomes
Because filgrastim was the most common drug used, we examined for associations between the dose of filgrastim used and successful outcome. We recorded successful rechallenge rates for patients where the index episode was agranulocytosis (ANC <0.5 Â 10 
Data Extraction
Articles included were critically reviewed by 2 authors (J.L. and S.M.), and the following information was extracted where possible: age, sex, ethnicity, number of previous clozapine (re-) challenges, severity of initial neutropenia, G-CSF/GM-CSF dose, frequency and type of G-CSF used, duration of follow up, and successful outcome, defined as continuation of clozapine treatment or not, alternative causes of neutropenia, and adverse events. We did not undertake a risk of bias assessment of the included studies because most of them were case series/reports.
RESULTS

Study Selection, Study, and Participant Characteristics
The study selection process, search results, and reasons for exclusion are given in Figure 1 .
The initial search yielded 766 references. After checking titles and abstracts, 57 full texts were screened. This selection process refined the number of relevant articles to 16 clinical reports, 6 of which were case series and 10 of which were case reports. No interventional or observational studies were identified.
We identified 32 episodes (in 31 patients) of clozapine rechallenge, where G-CSF was prescribed as maintenance prophylaxis (n = 23) [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] or as single, as-required administrations (n = 9) 13, 14, [20] [21] [22] [23] [24] to enable continued clozapine treatment.
Cause of the Initial Neutropenic Episode
An appraisal of potential alternative explanations for the initial neutropenia (eg, viral illness and other drug treatments) was documented in 6 of the 32 patients. Four patients provided sufficient information to indicate that a "true" clozapine-induced neutropenia or agranulocytosis had occurred, 9, 17, 20, 24 whereas in 2 patients, other contributing factors were identified. 15, 19 
G-CSF in Clozapine Rechallenge
Twenty-three of the 32 patients identified received continual G-CSF as prophylaxis (mean [SD] duration of G-CSF use, 8.8 [4.2] months; median, 11 months; range, 1.25-13 months), whereas 9 received G-CSF as required (there were no cases reported where as-required G-CSF was prescribed but not administered).
Seventy five percent (n = 24) of patients remained on clozapine with the support of regular G-CSF (n = 16) or after asrequired G-CSF administrations (n = 8; mean [SD] duration of follow-up, 11.8 [5.4] months; median, 12 months; range, 5-30 months), whereas in 25% (n = 8) of patients, clozapine was discontinued because of recurrence of neutropenia or an attenuated response to G-CSF suggesting an enhanced risk of agranulocytosis leading to a clinician initiated discontinuation. Seventy percent (n = 16) of patients in receipt of continual prophylactic G-CSF were successfully maintained on clozapine for an average (SD) follow-up period of 10.9 (2.5) months (median, 12 months; range, 5-13 months). The mean (SD) time to clozapine discontinuation in those treated with continual G-CSF (n = 6) was 3.0 (2.8) months (range, 0.25-7 months). Seventy-eight percent were treated with filgrastim (n = 25), 16% were treated with lenograstim (n = 5), and the other 2 patients were treated with G-CSF (formulation not specified) and GM-CSF. Fifteen patients received G-CSF weekly and 7 twice weekly, with 2 receiving filgrastim 480 μg daily. Seventy-one percent of those treated with continual filgrastim (n = 15) and 50% of those treated with continual lenograstim remained on clozapine (n = 1). The characteristics of G-CSF use and associations with continued clozapine use are shown in Table 1 .
Seventy-four percent of patients where sex was specified were male (17/23), with 76% of white ethnicity (n = 19) and 20% of black ethnicity (n = 5). Eighty-four percent (n = 16/19) of those of white ethnicity remained on clozapine compared with 60% (n = 3/5) of those of black ethnicity.
Previous Neutropenic Episode and Outcomes During Rechallenge
Data were available for 17 of the cases regarding the degree of neutropenia at the index clozapine discontinuation, with 7 cases having had agranulocytosis (ANC 0.1-0.5 Â 10 an index episode of severe agranulocytosis had a recurrence of agranulocytosis (ANC 0.3 Â 10 9 /L) on a first rechallenge, while treated with G-CSF 300 μg twice weekly, and subsequently had a second rechallenge, supported on G-CSF 480 μg twice weekly, and was successfully maintained on clozapine at the time of follow-up (12.5 months; mean ANC, 15. 
Adverse Events
Only 9 patients reported on adverse events relating to G-CSF use. Two had evidence of a rebound leukocytosis, 15, 20 whereas in another case, a mild subjective euphoria in the hours after G-CSF administration was reported. 9 The other 6 cases did not have any adverse events associated with G-CSF use. 13, 18, 22, 24 
DISCUSSION
In this first systematic review of the use of G-CSF to support clozapine rechallenge and maintenance, it seems that G-CSF is an effective strategy for some people. Seventy-five percent of cases were able to continue clozapine with the use of G-CSF, either as regular prophylaxis (70% success rate) or as as-required administrations (89% success rate).
Our review findings provide the largest synthesis of cases where G-CSF has been used to prevent recurrence of neutropenia and/or to allow for the continuation of clozapine. In most published cases, the use of G-CSF enabled clozapine to be continued for at least 10 months. This is in keeping with a recent systematic review where clozapine rechallenge was successful in 78 (70 %) of 112 patients after neutropenia. 6 We identified that 60% of those with an index episode of agranulocytosis had a successful outcome with continual G-CSF use, a higher figure than the 3 (20 %) of 15 patients with a successful rechallenge after agranulocytosis in the review by Manu et al. 6 That same review examined 11 cases of rechallenge after neutropenia in which 7 patients successfully continued clozapine while receiving G-CSF. 6 Our review expands on this by identifying 32 episodes in which G-CSF was used to support clozapine rechallenge or clozapine continuation in cases where low neutrophil counts led to interruption of treatment.
Rechallenge after neutropenia or agranulocytosis is a risky enterprise and a complex clinical decision, especially as the long-term consequences of maintenance G-CSF treatment in the absence of a primary hematological problem are unclear. Nevertheless, our findings suggest that in some cases, G-CSF can be successfully used to facilitate the successful reinitiation and maintenance of clozapine, although there are insufficient data systematically examining adverse outcomes to be able to comment authoritatively on safety.
Limitations
Our findings must be viewed in relation to limitations in the primary study data. Only 6 of the reported cases provided an evaluation for non-clozapine-related causes of the initial neutropenia event. This raises the possibility that some of the index events may not have been a true clozapine-induced neutropenia, but neutropenia secondary to alternative non-clozapine factors, a commonly encountered scenario in specialist clinical practice. The risk for neutropenia recurrence during clozapine rechallenge depends on whether the index event was truly caused by clozapine or not. The paucity of data relating to this important factor in the cases identified in this review means that some of the cases reported may not represent true clozapine-induced neutropenia. Any non-clozapine-related neutropenic and agranulocytosis episodes may have contributed to the successful rechallenge, raising the possibility of an overestimation of the rate of successful rechallenge.
There were no controlled studies available, and there is a need for caution in interpreting data relating to case reports and case series. 25 Case reports alone cannot provide an accurate or quantitative measure of the risk for complications or death associated with a drug or treatment intervention such as this. A publication bias for cases in which rechallenge was successful is probable. Furthermore, unreported deaths or severe adverse reactions may have occurred during the use of G-CSF. A prospective placebo-controlled trial to establish the efficacy of G-CSF in clozapine rechallenge would be the criterion standard approach to establish this, although the rarity of clozapine rechallenge may make such a study impractical outside highly specialized centers. As such, multicenter observational and retrospective studies to establish the efficacy of G-CSF in clozapine-associated agranulocytosis would be the first choice for future research.
CONCLUSIONS
We provide further evidence that the use of G-CSF can support successful clozapine rechallenge after discontinuation because of an episode of neutropenia/agranulocytosis. However, given the paucity of systematically reported data on this topic and the reliance on case reports which may be subject to publication bias, these results should be interpreted with caution. From the available data, it is not possible to recommend this course of action for someone with a true clozapine agranulocytosis.
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